

**THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.**

**Genflow Biosciences Plc**

**Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs**

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces positive preliminary interim results from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical trial evaluating its proprietary SIRT6 centenarian gene therapy in aged dogs.

**Trial overview**

The randomised, blinded study, conducted by an independent contract research organisation, enrolled 24 beagle dogs aged over 10 years who were allocated to four groups: two naked DNA treatment cohorts at different dose levels, a single-dose AAV8 cohort, and a control group.

The interim analysis reflects outcomes observed during the dosing period. Additional endpoints remain under assessment.

**Preliminary interim results**

All treatment groups demonstrated superior survival compared to the control group during the dosing period. No adverse events were observed, and all treatment modalities exhibited a favourable safety and tolerability profile suitable for use in aged companion animals.

Across treatment cohorts, improvements were observed in several functional and observable endpoints, including quality of life, muscle mass preservation, frailty index reduction, and coat quality, relative to control animals, which exhibited expected age-related decline.

**Ongoing analyses**

Several key endpoints remain under evaluation, including biological age determination using methylation clock analysis and comprehensive muscle biopsy histology. These analyses are intended to provide further mechanistic and quantitative validation of the therapy's effects. The Company expects to provide a comprehensive update on all remaining endpoints within approximately two months.

**Commercial and strategic implications**

Genflow believes these preliminary results support the potential of its SIRT6 gene therapy as a first-in-class approach to addressing age-related decline in companion animals and reinforce the programme's relevance to prospective animal health partners. The Company is actively engaging with animal health companies regarding potential licensing, co-development, and commercialisation opportunities.

Dr Eric Leire, Chief Executive Officer of Genflow Biosciences said: "These preliminary interim results represent a significant milestone for Genflow and significantly strengthen our position for animal health partnerships. The consistency of positive signals across multiple independent endpoints from survival and quality of life to measures of muscle preservation and frailty reduction, combined with an excellent safety profile, supports our SIRT6 platform as a credible, differentiated asset for the companion animal market."

Based on these encouraging preliminary findings, we are proceeding with the follow-up phase to assess durability of effects and to monitor for differences in age-related disease emergence - data that will inform future commercial discussions. We expect to provide a comprehensive update on all endpoints, including the critical methylation clock and muscle histology data, within two months."

**Contacts**

**Genflow Biosciences**

Dr Eric Leire, CEO

+32-477-495-881

**Harbor Access**

Jonathan Paterson, Investor Relations

+1 475 477 9401

[Jonathan.Paterson@Harbor-access.com](mailto:Jonathan.Paterson@Harbor-access.com)

**About Genflow Biosciences**

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies for age-related diseases, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH(Metabolic Dysfunction-Associated Steatohepatitis) the most prevalent chronic liver disease for which there is no effective treatments. Please visit [www.genflowbio.com](http://www.genflowbio.com) and follow the Company on [LinkedIn](#) and [X](#).

## **DISCLAIMER**

The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lse.com](mailto:ms@lse.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCUARVRNUUUAR